Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

DISEASE CHARACTERISTICS:

* Radiologically or histologically confirmed hepatocellular carcinoma

  * Stage III or IV primary disease
  * Recurrent, unresectable, or metastatic disease meeting any of the following criteria:

    * Pancreatic cancer that underwent prior surgical resection and progressed with recurrent metastatic disease to the liver
    * Gastric, colon, breast, or ovarian cancer or melanoma with metastatic disease to the liver
    * Primary or recurrent disease that cannot be surgically resected leaving the patient disease-free
* Radiologically measurable disease
* Ineligible for liver transplantation according to University of San Francisco listing criteria:

  * Single lesion \> 6.5 cm
  * Three or more tumors \> 4.5 cm
  * Cumulative tumor diameter \> 8 cm

PATIENT CHARACTERISTICS:

* Karnofsky performance status 60-100%
* ANC ≥ 1,500/mm³
* Platelets ≥ 75,000/mm³
* Creatinine ≤ 1.7 mg/dL
* Total bilirubin ≤ 1.5 mg/dL
* AST and ALT ≤ 3 times the upper limit of normal
* INR \< 1.5
* LVEF ≥ 50%
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No serious concurrent infection or medical illness that would render the protocol treatment unsafe
* LVEF ≥ 50%

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No concurrent steroids